Education
About Us
Working with TipRanks
Follow Us
Saniona AB (SE:SANION)
:SANION
SANION Stock Chart & Stats
kr21.15
-kr0.15(-2.06%)
At close: 4:00 PM EST
kr21.15
-kr0.15(-2.06%)
Day’s Range― - ―
52-Week Rangekr5.41 - kr22.40
Previous CloseN/A
Volume191.43K
Average Volume (3M)1.06M
Market Cap
€3.03B
Enterprise Valuekr1.11B
Total Cash (Recent Filing)€308.24M
Total Debt (Recent Filing)€6.41M
Price to Earnings (P/E)4.6
Beta-0.91
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.39
Shares Outstanding138,030,140
10 Day Avg. Volume913,988
30 Day Avg. Volume1,064,614
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.69
Price to Sales (P/S)2.56
P/FCF Ratio3.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Saniona AB News
SANION FAQ
What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest stock price was kr5.41 and its highest was kr22.40 in the past 12 months.
What is Saniona AB’s market cap?
Saniona AB’s market cap is €3.03B.
When is Saniona AB’s upcoming earnings report date?
Saniona AB’s upcoming earnings report date is Feb 26, 2026 which is in 70 days.
How were Saniona AB’s earnings last quarter?
Saniona AB released its earnings results on Nov 27, 2025. The company reported kr2.391 earnings per share for the quarter, beating the consensus estimate of N/A by kr2.391.
Is Saniona AB overvalued?
According to Wall Street analysts Saniona AB’s price is currently Overvalued.
Does Saniona AB pay dividends?
Saniona AB does not currently pay dividends.
What is Saniona AB’s EPS estimate?
Saniona AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Saniona AB have?
Saniona AB has 138,030,140 shares outstanding.
What happened to Saniona AB’s price movement after its last earnings report?
Saniona AB reported an EPS of kr2.391 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 14.491%.
Which hedge fund is a major shareholder of Saniona AB?
Currently, no hedge funds are holding shares in SE:SANION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Saniona AB
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Xspray Pharma AB
―
Cantargia AB
―